From: Stock Gumshoe<[email protected]>
Subject: The Regulatory Maze: What it means for our health
Preheader: Doc Gumshoe looks at patents, clinical trials and more...
Reply: [email protected]
Please unsubscribe if you don't want Stock Gumshoe emails. 
If this message is not clearly formatted in your email, click here for the web version

DAILY UPDATE
December 19, 2017
Dear Valued Reader,

Today I hand the baton over to Doc Gumshoe, who has a great overview article for you about what the regulatory framework looks like for drugs -- what's a patent, how does a clinical trial work, and what does that mean for our health?  He doesn't recommend stocks, but this is great info for any investor to understand... and, of course, anyone who ever gets sick.  Just click below for...


With individual stock selection now more critical than ever, this report is designed to bring you some of our top ideas for the year ahead. One of the companies highlighted in this report controls the smartphone market and now has its sights set on owning a bigger technology. It has the potential to be the most valuable stock in the history of investing. You need to find out the name of this company before the rest of the market does.

This Report Is Completely Free, Download Your Copy Today


Advertisement

Another Monday, another teaser pitch from the Motley Fool -- they're selling subscriptions to their Stock Advisor service by hinting at a "rare recent IPO buy alert" that they say was brought down by selling as the lockup period ended... and, in their words, "this could be the lowest we ever see their stock!”  So what are we dealing with here?  Just click below to...


Disclaimer: Nothing in this email or in the linked articles should be considered to be individual investment advice -- we can't tell you what you should do with your money, we can just share our opinions and perspective. Our authors try to use reliable information sources but also make mistakes of both fact and judgement on occasion, so all assertions should be checked and confirmed. You should speak with your financial advisor and understand everything fully before committing money to any investment.

Most issues of this email newsletter include advertising, and it should not be assumed that the presence of an advertisement means that the product or service advertised is endorsed by Stock Gumshoe or the author. For full disclaimers, disclosure information, and privacy policies please see the prominent links at the bottom of each page at StockGumshoe.com.

If you wish to unsubscribe to these mailings, there are links at both the bottom and top of this email that you can use to do so permanently and safely, we have no wish to email people who don't want to receive these messages. Please note that unsubscribing using the link below applies only to receiving emails, if you are a member of the Stock Gumshoe Irregulars that membership will not automatically change or be canceled. Please contact us if you need to change a paid membership.
Unsubscribe
Stock Gumshoe, 351 Pleasant St., Suite B #205, Northampton, MA 01060